SLC5A2 and hepatocellular carcinoma: These results suggest the potential protective effects of SGLT2 inhibitors against HCC development in high-risk patients, reinforcing the importance of targeted therapeutic strategies for managing HCC risk in patients with diabetes and chronic viral hepatitis.